Findings of a new phase 2 trial published in The New England Journal of Medicine cited that treatment with itepekimab, a new human IgG4P monoclonal antibody against the upstream alarmin interleukin-33, led to a notable improvement in lung function compared with placebo in patients with moderate to severe asthma. Blockade with itepekimab also led to a reduction in events that indicate loss of asthma control. However, the results for a subgroup of patients treated with itepekimab in combination with dupilumab, an anti-interleukin-4 receptor subunit α and -13 monoclonal antibody, were not favorable in comparison with placebo, according to the trials report.